| Ytd | -53.88% | |
| 1y | 153.96% |
| Open | Prev Close | 11.59 | Low | High | Mkt Cap | 1.01B | |||
| Vol | 805.00 | Avg Vol | 1.44M | EPS | -2.02 | P/E | -5.74 | Forward P/E | -4.80 |
| Beta | 2.00 | Short Ratio | 6.81 | Inst. Own | 119.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 11.89 | 200-d Avg | 17.42 | 1yr Est | 40.70 |
OLMA News
Study to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in app
Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-
Guggenheim analyst Brad Canino maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lower
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.52) per share which beat the an
Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-
US stocks fall as Dow Jones drops over 1% on Monday, while NASDAQ and S&P 500 also decline. Korn
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-
Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken pr
During Thursday, 849 stocks hit new 52-week lows.